Previous close | 984.64 |
Open | 988.00 |
Bid | 975.90 x 100 |
Ask | 978.29 x 100 |
Day's range | 966.34 - 988.17 |
52-week range | 684.81 - 998.33 |
Volume | |
Avg. volume | 453,613 |
Market cap | 106.944B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 28.88 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
Q1 2024 Intellia Therapeutics Inc Earnings Call